No abstract

No abstract

Brazilian private sector was estimated to lead to an incremental annual reduction from 10,000 to 20,000 influenza-related hospitalization (where 14,000 were respiratory-related hospitalization and 6,000 were cardiovascularrelated hospitalization), from 900 to 1800 influenza-related deaths, and 11,000 influenza-related general practitioner visits, corresponding to avoided costs from USD111 million (BRL454M) to USD219 million (BRL890M), depending on the hospitalization definition. Hospitalization avoided costs represented 99% of the total avoided costs. Conclusions: Switching to TIV-HD would significantly reduce the burden of influenza especially by reducing hospitalizations that represent the most important source of cost for private market.

lifetime horizon, with costs and outcomes discounted by 3.5% per year. Univariate and multivariate probabilistic sensitivity analyses are conducted to investigate parameter uncertainty. RESULTS: The incremental cost-effectiveness ratio (ICER) for vedolizumab is estimated at £21,620/QALY compared with CT. Sensitivity analyses showed that results are most sensitive to variation in the CT arm transition probabilities from the moderately-severely active state and from the remission state. The ICER was also sensitive to response assessed at week six rather than week 8 and efficacy based on GEMINI II only. When treatment with vedolizumab was continued for 2 or 3 years (instead of 1 year) the ICER increased to £24,695/QALY and £26,207/QALY respectively. The average probabilistic ICER shows vedolizumab to be £27,428/QALY gained (95% CI ICER of -£7,883 to £82,947). CONCLUSIONS: The economic model predicts that treatment with vedolizumab improves QALYs and is a cost-effective alternative to CT for patients who have inadequate response to CT and TNF-a antagonists. Vedolizumab has received positive recommendations from the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) for the CT and anti-TNF failure population. PSY115OBJECTIVES: An increase in blood-serum-potassium levels is common in patients with renal impairment or heart failure. Lifesaving RAAS-inhibitors (RAASi) such as ACE inhibitors, AT1 receptor-antagonists and aldosterone-blockers lead to a further rise in potassium levels. Discontinuation and downtitration of RAASi result in increased morbidity, as RAASi prolong the time to complete renal insufficiency. The purpose of this study was to extend the results of an 8-week OPALeHK RCT for patiromer, a nonabsorbed potassium-binder, that showed significant reduction in hyperkalaemia and RAASi dose maintenance in the patiromer group (94%) compared to no-patiromer (placebo) arm (44%). The analysis was performed from the Austrian healthcare-systems perspective. METHODS: A reported model by Sutherland et al. (2017), composed of a decision-tree and a Markov process, was used to simulate the treatment pathway of patients with chronic-kidney-disease (CKD). The short-term decision-tree estimates the proportion of CKD patients (potassium level, 5.0mmol/L) that continued/discontinued RAASi medication after hyperkalemia. The endpoint of the decision-tree was linked with to Markov model to simulate life-time follow-up. The model includes 6 states (stable CKD, CKD disease-progression, cardiovascular (CV) events, post CV event, hospitalization and death). The cohort definition was adopted from the OPALeHK trial. Monte-Carlo simulation accounted for uncertainty. Direct costs and life expectancy were obtained from local sources for 2018. QALYs and costs were discounted at 5% p.a. RESULTS: Over lifetime, costs and outcomes associated with patiromer would amount to 38,117.17V and achieve 5.48 QALYs. Costs with no treatment are 27,157.66V and obtain 4.90 QALYs. The results show that pati...

HFrEF progression and associated lifetime outcomes. To estimate treatment effects and utilities, the model was calibrated with data from the PARADIGM-HF trial. Baseline population characteristics were adapted to match a real-world population of patients already being treated with sacubitril/valsartan (patients from an observational study conducted in Portugal, the PRiMe study). Results are expressed as hospitalizations and deaths estimated to be avoided, as well as life-years (LY) and quality adjusted life-years (QALY) estimated to be gained with sacubitril/valsartan versus enalapril. A 5-year time horizon and a 5% discount rate were considered. Results: Assuming that the total number of patients treated with sacubitril/valsartan are persistent and that they have the same baseline characteristics as the patients recruited in the PRiMe study, after 5-years of treatment, we estimate to have avoided 2,553 hospitalizations (647 hospitalizations due to HF, 946 due to other cardiovascular events and 960 non-cardiovascular). Similarly, a total of 494 deaths are estimated to be avoided after 5-years versus a scenario with enalapril. A benefit of 1,161 LY and 1,173 QALY gained over a period of 5-years is also estimated. Conclusions: Sacubitril/valsartan is estimated to have a high impact on morbidity and mortality in the Portuguese population which is shown by the number of hospitalizations and deaths estimated to be avoided and LY and QALY estimated to be gained in the currently treated population.